A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.

Clinical cancer research today often includes testing the value of biomarkers to direct treatment and for drug development. However, the practical challenges of integration of molecular information into clinical trial protocols are increasingly appreciated. Inherent difficulties include evidence gap...

Full description

Bibliographic Details
Main Authors: Hall, J, Salgado, R, Lively, T, Sweep, F, Schuh, A
Format: Journal article
Language:English
Published: Lancet 2014
_version_ 1797051087885172736
author Hall, J
Salgado, R
Lively, T
Sweep, F
Schuh, A
author_facet Hall, J
Salgado, R
Lively, T
Sweep, F
Schuh, A
author_sort Hall, J
collection OXFORD
description Clinical cancer research today often includes testing the value of biomarkers to direct treatment and for drug development. However, the practical challenges of integration of molecular information into clinical trial protocols are increasingly appreciated. Inherent difficulties include evidence gaps in available biomarker data, a paucity of robust assay methods, and the design of appropriate studies within the constraints of feasible trial operations, and finite resources. Scalable and proportionate approaches are needed to systematically cope with these challenges. Therefore, we assembled international experts from three clinical trials organisations to identify the common challenges and common solutions. We present a practical risk-assessment framework allowing targeting of scarce resources to crucial issues coupled with a library of useful resources and a simple actionable checklist of recommendations. We hope that these practical methods will be useful for running biomarker-driven trials and ultimately help to develop biomarkers that are ready for integration in routine practice.
first_indexed 2024-03-06T18:14:52Z
format Journal article
id oxford-uuid:044691d4-e4aa-4886-b17a-b1da38398c5f
institution University of Oxford
language English
last_indexed 2024-03-06T18:14:52Z
publishDate 2014
publisher Lancet
record_format dspace
spelling oxford-uuid:044691d4-e4aa-4886-b17a-b1da38398c5f2022-03-26T08:50:52ZA risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:044691d4-e4aa-4886-b17a-b1da38398c5fEnglishSymplectic Elements at OxfordLancet2014Hall, JSalgado, RLively, TSweep, FSchuh, AClinical cancer research today often includes testing the value of biomarkers to direct treatment and for drug development. However, the practical challenges of integration of molecular information into clinical trial protocols are increasingly appreciated. Inherent difficulties include evidence gaps in available biomarker data, a paucity of robust assay methods, and the design of appropriate studies within the constraints of feasible trial operations, and finite resources. Scalable and proportionate approaches are needed to systematically cope with these challenges. Therefore, we assembled international experts from three clinical trials organisations to identify the common challenges and common solutions. We present a practical risk-assessment framework allowing targeting of scarce resources to crucial issues coupled with a library of useful resources and a simple actionable checklist of recommendations. We hope that these practical methods will be useful for running biomarker-driven trials and ultimately help to develop biomarkers that are ready for integration in routine practice.
spellingShingle Hall, J
Salgado, R
Lively, T
Sweep, F
Schuh, A
A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
title A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
title_full A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
title_fullStr A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
title_full_unstemmed A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
title_short A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group.
title_sort risk management approach for effective integration of biomarkers in clinical trials perspectives of an nci ncri and eortc working group
work_keys_str_mv AT hallj ariskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT salgador ariskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT livelyt ariskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT sweepf ariskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT schuha ariskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT hallj riskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT salgador riskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT livelyt riskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT sweepf riskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup
AT schuha riskmanagementapproachforeffectiveintegrationofbiomarkersinclinicaltrialsperspectivesofanncincriandeortcworkinggroup